gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin file valrox roche-onc extend
highlight week juli juli unrat announc plan make us
europ regulatori submiss gene therapi gt valrox valoctocogen roxaparvovec
hemophilia hema could make valrox first hemophilia gt product review regulatori agenc
spark neutral file announc roch unrat spark agre extend extend
end date regard spark acquisit april order provid parti addit time satisfi
regulatori condit respect anti-trust law spark develop hemophilia gt asset
may driver roch interest spark freelin privat present intern societi
thrombosi haemostasi isth annual congress melbourn follow-up data cohort
b-amaz phase i/ii trial gene therapi gt treatment hemophilia
hemb patient treat factor ix level week liver enzym remain normal
rang time point freelin also announc plan initi ind-en studi gt
hemophilia hema privat present isth hybrid aav/lipid nanoparticl lnp
approach gene edit mous model hema data demonstr stabl factor viii
fviii express month post-treat well possibl repeat dose titrat optim fviii level
targovax unrat announc data part phase trial oncolyt viru
combin keytruda patient refractori melanoma patient demonstr clinic respons
overal respons rate partial respons complet respons data
suggest abil induc innat adapt immun activ
look forward juli juli juli american associ cancer research
host meet san francisco call immun cell therapi cancer success challeng cell
form adopt therapi program includ repres unrat
privat unrat obsidian therapeut privat pact pharma privat
unrat juli american societi virolog asv host annual meet
minneapoli mn program includ repres neutral novarti unrat
report result juli edt presum provid updat zolgensma progress
weekli price move vivo genet medicin aav srna mrna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
studi publish juli buy privat co-found feng zhang
group broad institut report new crispr fusion enzym expand singl base edit rna roughli
doubl number pathogen mutat address rna base edit recal unlik standard crispr edit
produc mutat via imperfect repair dna break base edit promot direct convers base
anoth without break nucleic acid chain accomplish fuse deaminas domain differ
enzym onto inact crispr nucleas pair differ nucleas differ
deaminas domain approach appli base edit dna perman genom modif
time exposur rna transient edit challeng natur deaminas enzym typic perform
type convers eg convert cytosin base uracil limit sequenc modifi may
potenti show notabl off-target edit research rapidli address issu ration engin
direct evolut enhanc function
pleas refer import disclosur inform regul analyst certif found page report
studi broad scientist use approach gener rna base editor call rescu
catalyz cytosin uracil convers rna subsequ increas edit specif via addit round
engin proof-of-concept experi cell cultur show rna edit therapeut relev base includ
convers alzheim risk-associ allel protect variant excit note
earli day approach remain off-target edit detect variabl sometim low edit
rate apo gene proof concept thu far demonstr cell cultur said
long term rna base edit clear applic therapeut set perman dna modif
may undesir recoveri wound infect less-sever diseas indic risk/benefit
assess would favor perman edit broadli see studi signal continu rapid
technolog develop crispr space
chardan genet medicin alpha portfolio gmap articul convict view sector
open new pair trade long buy chardan top pick adverum neutral
updat chardan genet medicin alpha portfolio gmap perform follow
 chardan top pick genet medicin cumul alpha gener sinc march
 chardan genet medicin top pick averag alpha gener ytd
 chardan genet medicin top pick close averag alpha gener
 chardan genet medicin top pick close averag alpha gener
genet medicin news juli juli
unrat receiv fda track design gt pd-gba juli
blcm unrat announc rivo-cel met endpoint pi/ii trial cancers/blood disord juli
unrat appoint dr vijay yabannavar evp manufactur technic oper juli
unrat announc plan submit bla gt valrox hema juli
unrat complet enrol trial dna-bas immunotherapi vin juli
neutral file roch unrat extend acquisit agreement date april juli
trvx unrat report result pi trial oncolyt viru keytruda melanoma juli
targovax announc data part phase trial oncolyt adenoviru
combin keytruda patient refractori melanoma
patient treat intratumor inject week follow re-challeng
keytruda week safeti data show treatment regimen well toler patient demonstr clinic
respons overal respons rate partial respons complet respons
week prior start keytruda system increas pro-inflammatori cytokin observ
patient tnf and/or ifn tumor level increas infiltr cell seen patient
rel level activ cell grzb increas patient addit cell recogn
specif tumor antigen and/or found circul patient togeth data
suggest abil induc innat adapt immun activ
cll unrat publish swiff- new construct on/off switch juli
casebia tx privat present isth vivo gene edit hema juli
casebia present isth strategi homology-independ target
insert fviii mous model hema use hybrid aav/lnp approach human fviii transgen
deliv via follow lnp carri guid rna
recal casebia previous present data program american societi gene cell therapi
asgct annual meet show fviii activ normal target fviii gene albumin gene
locu isth casebia report target addit undisclos gene loci driven strong liver promot
achiev higher fviii activ high normal depend lnp dose vg/kg
page
target promot differenti casebia approach albumin-target strategi
develop intellia buy logicbio buy unrat
note may research potenti advantag type lnp/aav hybrid approach
singl administr aav donor templat may possibl administ repeat dose crispr-lnp
compon sever month achiev desir dose level inde data demonstr dose
lnp week apart increas fviii activ stepwis fashion within therapeut rang
freelin privat present aav-bas gt hemb announc new hema program juli
freelin present isth follow-up data cohort b-amaz phase i/ii trial
gt treatment hemb
patient cohort treat singl dose vg/kg month post-treat
patient liver enzym remain within normal rang time point level
patient free spontan bleed event requir supplement earlier data
patient present american societi hematolog annual meet decemb show
peak level patient week post-treat stabil
week post-treat post-treat
dose escal trial on-going freelin target level rang recal uniqur buy
chardan top pick develop gt use fix-padua variant present
isth data phase iib trial show mean activ week post-treat patient
receiv dose vc/kg
freelin also announc plan initi ind-en studi gt hema recal
sangamo unrat unrat present isth data phase i/ii trial
gt hema unrat plan submit bla
gt valrox hema per press releas freelin program design provid high consist
express rel low dose emphasi ad us reduc potenti manufactur pressur
unrat announc appoint liz mckee board director juli
tmuniti tx privat announc immunotherapi collabor match biotherapi privat juli
geneo tx privat announc patient dose dna-bas person vaccin gt-epic juli
tng fr unrat receiv mhra approv pi trial person vaccin hpv- scchn juli
passag privat announc gt manufactur agreement unrat juli
buy announc transit cfo replac jeff poulton juli
sight fp neutral complet enrol piii trial gt lhon juli
broad institut publish programm single-bas rna edit juli
mit publish vaccine-car-t combin approach improv immunotherapi efficaci juli
unrat announc ind clearanc arenavirus-bas immuno-tx hpv cancer juli
neubas tx privat announc complet revers merger ohrp unrat juli
compani mention report
page
page
select catalyst genet medicin coverag
figur alnylam arrowhead dicerna expect initi trial
select optim dose xlmtm
dcr-phxc initi long-term registr roll-ov studi ph
file ind cta pomp diseas
aro-aat initi phase ii/iii studi liver diseas
initi trial malign
complet ind-en studi diseas
dose patient phase studi mp
lumasiran initi illuminate-b -c phase trial
provid updat phase i/ii studi hemophilia
page
select catalyst genet medicin coverag
file ind pomp diseas
inclisiran report top-line data orion studi hypercholesterolemia
initi phase i/ii clinic trial huntington diseas
report dose escal data pi/ii trial achm/xlrp
report preliminari data phase i/ii studi batten diseas
initi phase i/ii trial dmd
submit ema lhon
report interim efficaci readout phase oval trial ovarian cancer
xlrp report interim data expans arm phase i/ii trial xlrp
dcr-hbv anticip first interim data clinic trial hbv
provid initi data phase trial gangliosidosi
provid earli data cohort phase i/ii pioneer trial n- rp
file ind phase ii studi diabet retinopathi dr
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
top-lin phase ii data treat deb patient chronic wound
initi phase i/ii trial autosom recess congenit ichthyosi
initi dose phase trial hemophilia
initi phase i/ii trial
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
updat dose escal pi/ii ignit trial dmd
provid updat initi safeti studi hemophilia without inhibitor
 aro-enac file clear cell renal cell carcinoma cystic fibrosi
 fc initi phase ii/iii trial newli diagnos glioblastoma
 fc safeti activ readout phase ib trial met solid tumor
submit ind methylmalon acidemia mma
present preclin data new gt program fabri pomp defici
initi phase i/ii trial sjogren syndrom
file ind initi phase i/ii trial al
file ind initi phase i/ii trial wet
file ind huntington diseas program
provid follow-up data piib dose-confirm studi hemb
initi phase i/ii trial
present top-lin data phase i/iia clinic trial wet
 fc report final analysi phase trial rhgg
declar develop candid aml
initi phase trial dystroph epidermolysi bullosa deb
figur alnylam/mdco meiragtx solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
file ind rett syndrom
initi phase trial recess dystroph epidermolysi bullosa
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
file ind inherit amyotroph later sclerosi
begin patient dose phase trial
initi pivot phase trial rdeb
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
dtx provid pi/ii cohort data glycogen storag diseas type ia gsdia
valrox present full piii top-line data hem
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
zolgensma anticip approv eu
initi phase ii trial /- cemiplimab cutan squamou cell carcinoma
initi phase trial /- solid tumor
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
present data phase portion solid tumor trial /- nivolumab
valrox submit bla pend fda feedback hemophilia
begin dose patient investigator-sponsor phase i/ii trial cystinosi
initi phase i/ii trial type gaucher diseas
bmn file ind phenylketonuria pku
initi phase i/ii trial leukocyt adhes deficiency-i
report initi phase data process fanconi anemia
initi phase ib trial beta-thalassemia
initi phase ii/iii trial dmd
initi phase studi pyruv kinas defici pkd
initi phase i/ii trial parkinson diseas mutat
initi phase trial multipl myeloma
initi clinic trial charcot-marie-tooth type
file approv transit clinic trial platform manufactur
rituximab report preliminari phase cohort expans data r/r nhl
micro-dystrophin initi pivot trial duchenn muscular dystrophi
hmaxi-k initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
zolgensma complet strong phase trial pre-symptomat sma type
initi phase i/ii studi best diseas
micro-dystrophin initi confirmatori trial commerci materi dmd
tegsedi expect approv brazil hattr amyloidosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
ptc-fa file ind friedreich ataxia fa enter clinic
sea-bcma report preliminari phase dose escal data r/r mm
lentiglobin initi phase studi sickl cell diseas
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma fibrocel buy lysogen oncosec medic oxford biomedica buy vbl neutral
figur select price movement week end juli vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm adverum genet therapytickerratingccm ptupsideclosechang changemc mm arbutu gene editingtickerratingccm ptupsideclosechang changemc mm homolog pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note though avx nite acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name rgl model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti ntech curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan recombinet
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
page
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
